Abstract
Description: The COVID-19 pandemic poses an unprecedented challenge for urologic oncology and radiotherapy. Radiation oncology departments and international collaboration groups are sharing their management adaptations made in response to the pandemic. The present narrative review summarizes the current recommendations.
 Relevance: There is a need to define which patients are candidates for safe treatment delay until the pandemic is over or controlled, to reduce exposure to the virus in the healthcare personnel and patients. 
 Conclusions: Telemedicine is recommended for follow-up visits. Active surveillance is the preferred treatment for patients with favorable intermediate risk. In greater risk disease, hormone therapy safely postpones radiotherapy up to 7 months. Radiosurgery is suggested in centers that have the necessary technology and previous experience. A moderately hypofractionated regimen is recommended if radiosurgery/ultra-hypofractionation is not available. Hypofractionation should be implemented if image-guided radiation therapy is already in place. Countries with low and middle-income economies face challenges in adopting the recommendations for prostate cancer management during the pandemic. Postponing treatment may result in the overwhelming of radiation oncology center capacity, after the pandemic.
Highlights
From the time the first patient was diagnosed with SARS-CoV-2 in Wuhan, China, incidence rates have risen rapidly in countries all over the world.[1]
Countries with high-income economies (HIEs) report higher incidence rates than countries with low and middle-income economies (LMIEs), the latter have higher mortality-to-incidence ratios.[6,7] Because more cases are diagnosed in the late stage of disease, radiation treatment is fundamental in the management of those patients.[8]. There is a pressing demand to define which patients require urgent or nonurgent treatment, until the pandemic is over, or at least controlled. [9,10]
Global initiatives to ensure adequate prostate cancer treatment are arising in response to the COVID-19 pandemic.[11,12] health systems and cancer care facilities in the countries with LMIEs have particularities that need to be considered when providing a recommendation for oncology care, in response to SARS-CoV-2
Summary
From the time the first patient was diagnosed with SARS-CoV-2 in Wuhan, China, incidence rates have risen rapidly in countries all over the world.[1]. Countries with high-income economies (HIEs) report higher incidence rates than countries with low and middle-income economies (LMIEs), the latter have higher mortality-to-incidence ratios.[6,7] Because more cases are diagnosed in the late stage of disease, radiation treatment is fundamental in the management of those patients.[8] There is a pressing demand to define which patients require urgent or nonurgent treatment (including a 2 to 4-month delay), until the pandemic is over, or at least controlled. Global initiatives to ensure adequate prostate cancer treatment are arising in response to the COVID-19 pandemic.[11,12] health systems and cancer care facilities in the countries with LMIEs have particularities that need to be considered when providing a recommendation for oncology care, in response to SARS-CoV-2
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
